JUST IN　•　WIRED

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

SHARE THIS STORYPLUS UNLOCKS FAVORITES READ LATER AND SOURCE CONTROL

The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.

READ ORIGINAL REPORT ↗

THIS JUST HAPPENED PACKAGES THE WORLD INTO A FAST LIVE FEED SOURCE REPORTING STAYS ONE CLICK AWAY

RELATED POSTSMORE HEALTH

HEALTH　•　BBC News

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

First personalised cancer vaccine cuts risk of disease returning in major trial

Rapid changes to care market risk to National Care Service, regulator says

Covid vaccine compensation scheme set for overhaul after Inquiry criticism

Running costs of vaccine damage scheme more than double amount paid to victims

Patient living in 'horrific pain' due to UK-wide drugs shortage

South Carolina's measles outbreak jumped to Washington state 5 times in 2 weeks

US says it killed five people in strike on alleged drug boat

The Ebola outbreak is breaking records -- and just marked a grim milestone